Evaluation and management of women with BRCA1/2 mutations.
Genetic counseling and testing for susceptibility to breast and ovarian cancer is often an integral component of management for women with a personal and/or family history of these malignancies. In this article, we will briefly review the function and genetic epidemiology of the two major susceptibility genes, BRCA1 and BRCA2. We will then address approaches to risk assessment for women at high risk with respect to the probability that they harbor a deleterious mutation in one of these genes, and the likelihood that they will develop cancer if such a mutation is identified. The process of genetic counseling and testing is discussed, including a summary of the potential benefits, limitations, and risks of testing as well as a summary of test result interpretation. We conclude with a review and appraisal of the various options for breast and ovarian cancer risk reduction and screening options for women with a BRCA1 or BRCA2 mutation.
Peshkin
Beth N
BN
Oncology and Medicine Department of Cancer Control, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Isaacs
Claudine
C
D001943:Breast Neoplasms / Q000235:genetics* / Q000628:therapy; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D005817:Genetic Counseling; D006801:Humans; D009154:Mutation; D010051:Ovarian Neoplasms / Q000209:etiology; D010052:Ovariectomy; D018570:Risk Assessment; D012308:Risk Management; D040242:Risk Reduction Behavior; D013629:Tamoxifen / Q000627:therapeutic use
D013629:Tamoxifen